Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Calistoga Pharma, a company engaged in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, has named Andrew Guggenhime as chief financial officer (CFO).
Subscribe to our email newsletter
Before joining the company, Guggenhime served as senior vice president and CFO of at Facet Biotech and as PDL BioPharma as senior vice president and CFO.
During his tenure at Facet and PDL, he was responsible for the finance, investor relations, program management, information technology and corporate services organisations.
Calistoga Pharma president and CEO Carol Gallagher said that Andrew brings a broad range of experience in strategic processes, financing strategies, and financial oversight as well as relationships with the investment community that will greatly benefit Calistoga.
“As we move into late-stage development with CAL-101, we are expanding both our business and scientific expertise,” Gallagher said.